SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-QSB                   
Quarterly Report Pursuant to Section 13 or 15 (d) of
the Securities Exchange Act of 1934

For the quarterly period ending			        Commission File 
October 1, 1995                           Number   0-3063

TINSLEY LABORATORIES, INC.
____________________________________________________________
(Exact name of registrant as specified in its charter)

           
California                       94-1049146
State or other jurisdiction of			(I.R.S. Employer Identification No.)
incorporation or organization			             


3900 Lakeside Drive, Richmond, California 94806
_______________________________________________________________
(Address of principal executive offices and zip code)


Registrant's telephone number, including area code (510)222-8110 


Indicate by check mark whether the registrant (1)  has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act  
of 1934 during the past 12 months (or for such shorter period that the 
registrant was required to file such reports), and (2) has been subject to 
such filing requirements for the past 90 days.  Yes X No __

767,124 shares of Common Stock outstanding as of October 1, 1995.

<PAGE>

Part 1.  Financial Information
Item 1.
<TABLE>
TINSLEY LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(Unaudited)

<CAPTION>
                                      Oct  1,          Dec 26,
                                       1995             1994
                                    ----------        ----------
<S>                                <C>              <C>
ASSETS
Current Assets:
  Cash and short-term investments     $373,179         $893,241 
  Accounts receivable                2,345,774        2,684,667 
  Inventories                        1,791,874        1,516,527 
  Prepaid expenses & other             328,612          272,253 
                                    ----------       ----------
  Total current assets               4,839,439        5,366,688 

Net property, plant & equipment      5,163,917        4,895,000 
Other assets                           909,389          940,887 
Net goodwill                         1,547,506        1,639,135 
                                    ----------       ----------
                                   $12,460,251      $12,841,710 
                                    ==========       ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
  Trade account payable               $638,626         $583,419 
  Current income taxes                 219,044          226,982 
  Other accrued liabilities          1,109,479        1,238,479 
                                     ---------        ---------
  Total current liabilities          1,967,149        2,048,880 

Long-term debt                         942,651        1,047,938 

Long-term notes payable
   to related parties                  460,000          860,000 

Deferred income taxes                  440,947          440,947 

Deferred compensation                  307,977          295,602 

Stockholders' Equity:
  Common stock at stated value         127,857          127,004 
  Capital in excess of stated value  1,343,877        1,316,680 
  Retained earnings                  6,869,793        6,704,659 
                                     ---------        ---------
Total stockholders' equity           8,341,527        8,148,343 
                                     ---------        ---------
                                   $12,460,251      $12,841,710 
                                    ==========       ==========
</TABLE>
<PAGE>


<TABLE>
TINSLEY LABORATORIES, INC.
Condensed Consolidated Statements of Income
(Unaudited)
<CAPTION>


                               Three months ended       Nine months ended
                               ------------------       ----------------
                               Oct  1,      Sep 25,     Oct  1,      Sep 25,
                                1995         1994        1995         1994
                              ---------    ---------   ---------   ---------
<S>                          <C>          <C>         <C>         <C>
Net sales                    $3,558,842   $2,974,360  $9,840,269  $9,783,441
Cost of sales & expenses      3,336,695    2,754,935   9,221,987   9,088,324
                              ---------    ---------   ---------   ---------
Income from operations          222,147      219,425     618,282     695,117

Amortization of goodwill
  & intangibles                  55,543       55,543     166,629     166,629
Other (income) expense            5,012      (31,362)    114,620     133,210
                              ---------    ---------   ---------   ---------
Income before taxes             161,592      195,244     337,033     395,278

Provision for taxes on income    77,400       91,108     171,900     195,134
                              ---------    ---------   ---------   ---------
Net income                      $84,192     $104,136    $165,941    $200,144

Per share of common stock:
  Net income                      $0.11        $0.14       $0.22       $0.26
</TABLE>

Notes:
Per share data are based on 767,124 shares issued and outstanding in 1995
 and 762,024 shares in 1994.
<PAGE>

TINSLEY LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

<TABLE>
<CAPTION>

                                        For the nine months ended
                                        --------------------------
                                         Oct  1,           Sep 25,
                                          1995              1994
                                        ---------         ---------
<S>                                     <C>               <C>
Cash flows from operating activities:
  Net income (loss)                       $165,133         $200,144 

  Adjustments to reconcile net
   income to net cash provided 
   (used) by operating activities:
  Depreciation & amortization              688,122          642,529 
  Change in operating assets and
    liabilities                           ( 55,517)        (627,026)
                                         ----------       ----------
    Net cash provided by operating
     activities                            797,738          215,647 

Cash flows from investing activities:
  Purchase of fixed assets                (790,410)        (441,130)
  Other                                    (43,500)          26,127
                                         ----------       ----------
     Net cash used in investing
      activities                          (833,910)        (415,003)

Cash flows from financing activities:
  Principal payments on long-term debt    (511,940)        (538,812)
  Other                                     28,050            2,375
                                         ----------       ----------
     Net cash provided by (used in)
      financing activities                (483,890)        (536,437)
                                         ----------       ----------
Net change in cash and cash
  equivalents                             (520,062)        (735,793)

Cash and cash equivalents at
  beginning of period                      893,241        1,182,654 
                                         ----------       ----------
Cash and cash equivalents at 
  end of period                           $373,179       $  446,861 
--------------------------------------------------------------------
Supplemental disclosure of cash
  flow information:
Cash paid for:
  Interest                                $151,987         $189,802 
  Income taxes                            $219,546         $113,886
--------------------------------------------------------------------

</TABLE>


<PAGE>



NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
October 1, 1995

Note:  1.	Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have 
been prepared in accordance with generally accepted accounting principles 
for interim financial information and with the instructions to Form 10-QSB 
and article 10 of Regulation S-X.  Accordingly, they do not include all of 
the information and footnotes required by generally accepted accounting 
principles for complete financial statements.  In the opinion of management, 
all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included.  Operating results for
the nine month period ended October 1, 1995 are not necessarily indicative 
of the results that may be expected for any future periods.  For further 
information, refer to the consolidated financial statements and footnotes 
thereto included in the Company's annual report on Form 10-KSB for the year 
ended December 25, 1994.

The consolidated financial statements include the accounts of Tinsley 
Laboratories, Inc., and its wholly owned subsidiaries, Century Precision 
Industries, Inc. d/b/a Century Precision Optics ("Century") and Tinsley 
International, Inc., after elimination of intercompany transactions and 
balances.

Note: 2.	Inventories

The components of inventory consist of the following:
<TABLE>
<CAPTION>

                                         October 1,         December 25,
                                           1995                1994
                                         ----------         ----------
<S>                                      <C>                <C>
Raw materials                              $288,203           $241,244 
Contracts in progress (net of 
cost of progress billings of 
$256,000 at October 1, 1995 and 
$136,000 at December 25, 1994)              600,827            594,759 
Finished goods                              902,844            680,524
                                          ----------         --------- 
                                         $1,791,874         $1,516,527 
                                          ==========         =========
</TABLE>
<PAGE>

MANAGEMENT'S DISCUSSION AND ANALYSIS
OF QUARTERLY FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

Item 2.

Sales for the first nine months of 1995 rose slightly to $9,840,269 from 1994
sales for the same period of $9,783,441.  Net income came to $165,133 or
22 cents a share, which is down from the $200,144 or 26 cents a share earned
last year.

Sales for the third quarter of $3,558,842 were up 20 percent from sales of
$2,974,360 for the September quarter a year ago.  Third quarter net income
of $84,192 or 11 cents a share declined 19 percent from net income of 
$104,136 or 14 cents a share earned in the comparable period of 1994.

Third quarter sales were moderately above those for the June quarter,
while third quarter net income strengthened appreciably over second
quarter earnings of $41,416 or 5 cents a share.

Profits for the first nine months continued to be adversely affected by
reduced military business, as well as by high initial start-up costs incurred
by certain new programs.

On the other hand we are encouraged by the higher backlog levels we are
experiencing in 1995, which increased to $6,907,000 by mid-year and held
at $6,277,000 at the close of September, well above backlog of $4,465,000
at the end of last year's third quarter and $4,000,000 at the start of the
current year.

Our existing pension and profit sharing plans have been frozen (curtailed)
as to the accrual of benefits for future services.  We believe that this 
curtailment does not create a significant gain or loss.  However, due to the
complexity involved in its calculation, the curtailment effect has not yet
been recorded. We anticipate that the complex calculations will be
completed during the fourth quarter of 1995.  We have implemented a
401(k) Profit Sharing plan to provide retirement benefits to employees.

Liquidity and Sources of Capital:

Cash provided by operations was $797,738 for the nine months ended
October 1, 1995, compared to $215,647 in the nine months ended
September 25, 1994.  The funds provided by net income plus depreciation
and amortization for the period, were partially offset by changes in working
capital accounts.  Funds of $338,893 were provided by accounts receivable
which decreased from the 1994 year end level.  Inventories increased
during the nine months, utilizing funds of $275,347.  Capital expenditures
of $790,410 and principal payments on debt of $511,940 were paid from
available cash during the nine month period.  The Company believes that
funds generated from operations should be sufficient to meet normal cash
flow requirements through the balance of 1995.  The Company has a
$1 million line of credit to draw upon for its short term needs.
<PAGE>

Part II   Other Information

Item 4.   Submission of Matters to a Vote of Security Holders

Reference is made to materials appearing with respect to election of the
Board of Directors, set forth in the Company's definitive Proxy Statment
filed in connection with the Company's 1995 Annual Meeting of 
Shareholders, held on April 26, 1995 which material is incorporated
herein.

Item 6.   Exhibits and Reports on Form 8-K

(b)  No reports on Form 8-K were filed during the current period.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

TINSLEY LABORATORIES, INC.



Robert J. Aronno
President and Chief Executive Officer